Published in Cancer Weekly, February 28th, 2006
On July 15, 2005, Geron announced a worldwide, exclusive license and collaboration agreement with Merck & Co., Inc., (MRK) which includes the grant of rights to Merck to develop anticancer therapies that target telomerase utilizing Merck's vaccine platforms. The agreement also grants Merck an exclusive option to Geron's dendritic cell-based telomerase vaccine. On February 1, 2006, Pharmexa, A/S, Horsholm, Denmark, which acquired GemVax in 2005, issued an announcement describing studies it intends to pursue with a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.